Future Market Insights (FMI) recently conducted a market study that projects the value of the worldwide veterinary biologics market will reach US$ 18.2 billion by 2029 and US$ 11.4 billion in 2022.
Rising trend of pet ownership across the world has increased concerns related to pet health, resulting in rising demand for veterinary biologics. According to the American Pet Products Association (APPA), around 67% of U.S. households own a pet, which is a significant rise of 56% since 1988. Preventive veterinary biologics such as vaccines are most widely used as prophylactic treatment. Increase in usage of prophylactic veterinary biologics is primarily attributed to growing awareness about better pet health management and risk of various diseases such as rabies. Recently, the World Health Organization (WHO) endorsed the use of veterinary biologics such as monoclonal antibodies over blood-derived rabies immunoglobulin. Such endorsements and quest for more safe & effective veterinary biologics have resulted in increased R&D spending.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-2288
Key Takeaways:
- Owing to rapid adoption of vaccines as a prophylactic treatment for better herd immunity, the segment is expected to be a significant revenue generator.
- Growing adoption of monoclonal antibodies for dermal disorder treatment in companion animals is anticipated to contribute to the dominance of the segment during the forecast period.
- Rising prevalence of infectious diseases in livestock has boosted the demand for veterinary biologics. Livestock is expected to be a significant revenue generating segment by animal type, during the forecast period.
- By distribution channel, the veterinary biologics market is dominated by veterinary clinics in terms of revenue, owing to direct customer contact for bulk orders.
- Europe is anticipated to be the most lucrative region in terms of revenue, due to growing adoption of animals for commercial use. East Asia is expected to witness notable growth during the forecast period.
Mergers & Acquisitions Key Strategy of Veterinary Biologic Manufacturers
Manufacturers such as Boehringer Ingelheim International GmbH, Zoetis Inc., etc., are engaging in mergers & acquisitions with small and medium regional players in the veterinary biologics market in order to streamline their product offerings in respective regions with diverse product portfolios.
Unlock exclusive insights with our expert analysts:
https://www.futuremarketinsights.com/ask-question/rep-gb-2288
More Valuable Insights on Veterinary Biologics Market
Future Market Insights brings a comprehensive research report on forecast revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each segment from 2014 to 2029. The global veterinary biologics market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the veterinary biologics market on the basis of product type (vaccines, monoclonal antibodies, bacterial extracts, immunomodulators, and allergenic extracts), animal type (companion animals, livestock, and equine), and distribution channel (veterinary clinics, veterinary hospitals, veterinary research institutes, and retail pharmacies), across seven major regions.
Veterinary Biologics Market By Category
By Product
- Vaccines
- Attenuated Live Vaccines
- Conjugate Vaccines
- Inactivated Vaccines
- Subunit Vaccines
- Toxoid Vaccines
- DNA Vaccines
- Recombinant Vaccines
- Bacterial Extracts
- Monoclonal Antibody
- Immunomodulatory
- Cytokines
- Others
- Allergenic Extracts
By Animal
- Companion Animals
- Canine
- Avian
- Feline
- Livestock
- Aquatic
- Bovine
- Porcine
- Ovine/Caprine
- Poultry
- Equine
By Distribution Channel
- Veterinary Clinics
- Veterinary Hospitals
- Veterinary Research Institutes
- Retail Pharmacies
By Region
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Unlock Tailored Insights: Customize Your Report for Maximum Impact :
https://www.futuremarketinsights.com/customization-available/rep-gb-2288
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube